Tim Chiang, an analyst from Capital One Financial, assigned the Buy rating on Jasper Therapeutics (JSPR – Research Report). The ...
Refinery29 on MSN3d
What It’s Like Living With Chronic Spontaneous Hives With No Known TriggerA little over a year ago, I woke up in the middle of the night with an itchy scalp. I didn’t give it much thought, assuming ...
Study C of the phase 3 LIBERTY-CUPID trial evaluated dupilumab as add-on therapy to standard of care antihistamines in biologic-naïve patients with CSU who remained symptomatic despite antihistamine ...
PARIS, France and TARRYTOWN, NY, USA I 11, 2024 I A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key ...
Sanofi has reported that Phase III LIBERTY-CUPID Study C of Dupixent in patients with chronic spontaneous urticaria met ...
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic ...
Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases. The French pharmaceutical company said Wednesday that the drug met the primary and all key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback